Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer

Burstein, HJ; Curigliano, G; Gnant, M; Loibl, S; Regan, MM; Loi, S; Denkert, C; Poortmans, P; Cameron, D; Thurlimann, B; Weber, WP; Panelists of the StGallen International Breast Cancer Consensus 2025

Author(s): Burstein, HJ; Curigliano, G; Gnant, M; Loibl, S; Regan, MM; Loi, S; Denkert, C; Poortmans, P; Cameron, D; Thurlimann, B; Weber, WP; Panelists of the StGallen International Breast Cancer Consensus 2025;
Details: Publication Year 2025-12,Volume 36,Issue #12,Page 1433-1446
Journal Title: Annals of Oncology
Publication Type: Guideline
Abstract: BACKGROUND: Breast cancer is a global disease affecting millions of individuals. Ongoing advancements in multidisciplinary management of breast cancer patients warrant discussion and integration into standard treatment plans. DESIGN: The St Gallen Breast Cancer Consensus conference is an international, biennial meeting where experts make treatment recommendations for state-of-the-art care of early stage breast cancer. RESULTS: Important innovations in the 2025 St Gallen recommendations include updated guidance on genetic testing; endorsement of hypofractionated, and ultra-hypofractionated, radiation therapy schedules for larger numbers of patients; recommendation for platinum-based chemotherapy in triple-negative breast cancer, and use of biological risk markers to consider anthracyclines in other breast cancer subtypes; avoidance of sentinel lymph node surgery in many patients with low-risk, estrogen receptor (ER)-positive cancers; use of immunotherapy in triple-negative and certain ER low-positive tumors; guidance for re-irradiation and systemic therapy in the setting of local-regional recurrence; criteria to guide treatment of oligometastatic breast cancer; and important recommendations for improving survivorship by minimizing neuropathy symptoms and addressing sexual health concerns of breast cancer patients. CONCLUSIONS: International, multidisciplinary guidance for early breast cancer is evolving and offers patients better outcomes, improved treatment choices, and greater concern for patient preferences and survivorship needs.
Publisher: Elsevier
Keywords: Humans; Female; *Breast Neoplasms/therapy/pathology/genetics; *Precision Medicine/methods/standards; *Patient Preference; Consensus; adjuvant endocrine therapy; axillary surgery; breast surgery; chemotherapy; ductal carcinoma in situ (DCIS); early breast cancer; immunotherapy; local-regional recurrence; oligometastatic breast cancer; radiation therapy; survivorship
Department(s): Medical Oncology
Publisher's Version: https://doi.org/10.1016/j.annonc.2025.09.007
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2025-11-06 11:44:57

Last Modified: 2026-01-13 02:21:06